2,400+ researchers supplied
99+ COAs published
6-panel tested every lot
Processing within 1–3 business days
FREE SHIPFree U.S. shipping on orders over $150Free U.S. shipping on orders over $150
Free U.S. shipping on orders over $150Snapshot:
Thymalin is a polypeptide isolated from the thymus gland and has been studied for its role in supporting immune function. Research suggests it has a role in influencing T-cell activity, cytokine modulation, oxidative defense, aging processes, and cellular resilience.
Thymalin is a polypeptide, naturally derived and isolated from the thymus gland [1]. Endogenous Thymalin naturally declines with age, paralleling thymic involution and reduced immune efficiency. It consists of short peptides, typically 2–8 amino acids in length, that support gene expression in immune and hematopoietic cells [1]. The dipeptide L-Glu-L-Trp, often referred to as the EW peptide, is the bioactive fragment with the most notable immunoregulatory properties [2]. Research demonstrates it can influence cytokine production, enhance communication between immune cells, and contribute to a healthier immune system responsiveness [2]. Because it can act at low concentrations, it has become a promising candidate in targeted immunomodulation strategies [1].
Although often confused with Thymulin, Thymalin is a polypeptide extract, while Thymulin is a zinc-dependent non-peptide hormone [1, 3]. Thymalin is thought to regulate thymic activity more broadly than Thymulin, which appears to enhance specific thymic hormone functions [1, 4].
Thymalin is clinically studied as a potential molecule that supports immune balance, antioxidant defenses, and tissue repair processes and promotes healthy cellular aging through multiple biologically active pathways.
Thymalin supports immune function by promoting T-cell differentiation, improving cytokine signaling, and enhancing lymphocyte activity [1]. In hematopoietic stem cells, it reduced the expression of CD44 and CD117, which are molecules associated with early stem cell proliferation and maintenance. This indicated a shift toward the development of mature immune cells [1]. These cell also had significant increases in CD28 expression, found on CD4+ and CD8+ T-lymphocytes, critical for T-cell activation and viral immunity [1].
In a comparative study, Thymalin significantly improved immune cell counts in those with respiratory viral infection, whereas standard therapy had minimal effects [5]. It increased total leukocyte counts by 25% and lymphocytes by 92%, despite lower baseline lymphocyte counts compared to controls [5]. Monocytes measured in blood rose by 55% with Thymalin compared to 42% on standard therapy, and eosinophils increased 4.6-fold versus 3.1-fold, respectively [5]. Thymalin also enhanced adaptive and innate immunity, raising T- and B-lymphocytes and NK cells by 2–2.4 times and boosting CD4+, CD8+, and CD3+HLA-DR+ cells by 2.2–3.4 times. In contrast, standard treatment including antiviral, antibiotics, and oxygen had no significant impact [5]. These findings suggest Thymalin has a role in restoring immune competence in conditions where immunity may be compromised.
Thymalin has demonstrated broad anti-inflammatory and regenerative potential. Its short peptide composition, particularly EW and KE dipeptides, can penetrate the cell nucleus and bind to specific DNA and histone regions [6]. This capability modulates gene expression involved in cytokine production, antioxidant defense, and tissue repair processes [5].
Molecular modeling shows that the EW and KE peptides interact with DNA regions that regulate key inflammatory genes, including ACE2, CYSLTR1, and CHUK – proteins deeply involved in driving cytokine-storm responses during severe viral infections [2]. In cell-based studies in a human mononuclear cell model of LPS-induced inflammation, Thymalin and its dipeptides reduced IL-1β, IL-6, and TNF-α by 1.4–6-fold, showing a direct capacity to downregulate pro-inflammatory cytokine synthesis [2].
Beyond acute immune modulation, thymalin may reduce oxidative stress, stabilize cyclic nucleotide balance, enhance neutrophil chemotaxis and phagocytosis, and support tissue regeneration [7]. Studies in various pathological models show reduced apoptosis and improved metabolic markers, suggesting that Thymalin helps restore cellular homeostasis and promotes recovery across multiple organ systems [7].
Geroprotective Benefits
Thymalin has been widely investigated for its geroprotective potential. Long-term studies in aging models show promising effects across multiple physiological systems, with potential to preserve cardiovascular, neurological, and metabolic function while reducing chronic, low-grade inflammation which is one of the major contributors to biological aging [4]. It appears to promote greater resilience and functional stability as the body ages, supporting T-cell production, normalizing cytokine activity, and influencing key regulatory pathways involved in immune and endocrine balance [4].
In one study spanning up to 8 years involving 266 older adults, researchers found Thymalin – either alone or combined with a pineal peptide – helped to normalize core physiological functions, including cardiovascular, endocrine, neurological, and metabolic markers [8]. Those receiving peptide therapy experienced a 2–2.4-fold reduction in acute respiratory infections, fewer cardiovascular complications, and improved bone health and had significantly lower mortality [8].
References
1 Khavinson, V. K., Linkova, N. S., Kvetnoy, I. M., Polyakova, V. O., Drobintseva, A. O., Kvetnaia, T. V., et al. (2020) Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells. Bull. Exp. Biol. Med. 170, 118–122 https://doi.org/10.1007/s10517-020-05016-z
2 Linkova, N., Khavinson, V., Diatlova, A., Petukhov, M., Vladimirova, E., Sukhareva, M., et al. (2023) The influence of KE and EW dipeptides in the composition of the Thymalin drug on gene expression and protein synthesis involved in the pathogenesis of a respiratory infection. Int. J. Mol. Sci., MDPI AG 24, 13377 https://doi.org/10.3390/ijms241713377
3 Reggiani, P. C., Schwerdt, J. I., Console, G. M., Roggero, E. A., Dardenne, M. and Goya, R. G. (2014) Physiology and therapeutic potential of the thymic peptide thymulin. Curr. Pharm. Des., Curr Pharm Des 20, 4690–4696 https://doi.org/10.2174/1381612820666140130211157
4 Reggiani, P. C., Schwerdt, J. I., Console, G. M., Roggero, E. A., Dardenne, M. and Goya, R. G. (2014) Physiology and therapeutic potential of the thymic peptide thymulin. Curr. Pharm. Des. 20, 4690–4696 https://doi.org/10.2174/1381612820666140130211157
5 Kuznik, B., Khavinson, V., Shapovalov, K., Linkova, N., Lukyanov, S., Smolyakov, Y., et al. (2021) Peptide drug thymalin regulates immune status in severe older patients. Adv. Gerontol., Pleiades Publishing Ltd 11, 368–376 https://doi.org/10.1134/s2079057021040068
6 Khavinson, V. K., Linkova, N. S., Chalisova, N. I. and Ivko, O. M. (2021) The use of thymalin for immunocorrection and molecular aspects of biological activity. Biol. Bull. Rev., Pleiades Publishing Ltd 11, 377–382 https://doi.org/10.1134/s2079086421040046
7 Avolio, F., Martinotti, S., Khavinson, V. K., Esposito, J. E., Giambuzzi, G., Marino, A., et al. (2022) Peptides regulating proliferative activity and inflammatory pathways in the monocyte/macrophage THP-1 cell line. Int. J. Mol. Sci., MDPI AG 23, 3607 https://doi.org/10.3390/ijms23073607
8 Khavinson, V. K. and Morozov, V. G. (2002) Geroprotective effect of thymalin and epithalamin. Adv. Gerontol., Adv Gerontol 10, 74–84
Research Use Only. All findings described above are derived from preclinical studies (animal models and in vitro experiments). Thymalin is not approved by the FDA for any diagnostic or therapeutic use in humans. Genesis Peptides makes no claims regarding human clinical efficacy. This product is sold exclusively for laboratory research.
Every lot undergoes six independent assays before release. Results are published in the lot-specific Certificate of Analysis.
Thymalin is a thymus-derived peptide drug, described as a polypeptide complex isolated from the thymus that regulates the functions of the immune system. The paper describes thymalin as a peptide preparation used in a standard and complex treatment method in patients with COVID-19. Thymalin, a pharmacopoeia peptide drug, was one of two peptide drugs whose immunomodulatory activity was studied alongside tinrostim.
In in vitro cell studies, thymalin appeared to stimulate differentiation of CD117+ cells into mature CD28+ T lymphocytes, as indirectly indicated by the findings. Thymalin increases the functional activity of T lymphocytes, but its targeted molecular mechanism requires further study. The authors suggest that thymalin's antiviral effect may consist in compensatory stimulation of HSC differentiation into CD28+ T lymphocytes at the stage of immunity suppression during an unfavorable viral infection course.
In an in vitro study, thymalin appeared to stimulate the differentiation of CD117+ cells into mature CD28+ T lymphocytes, and this was only indirectly indicated by the findings. The authors suggest that thymalin's antiviral effect may consist in compensatory stimulation of hematopoietic stem cell differentiation into CD28+ T lymphocytes when immunity is suppressed during an unfavorable viral infection course. One proposed mechanism of thymalin's immunomodulatory effect is its ability to influence the differentiation of human hematopoietic stem cells.
In a clinical trial in COVID-19 patients, adding Thymalin to standard therapy accelerated the decline of IL-6, C-reactive protein, D-dimer and indicators of the T cell system, compared with standard therapy alone. In COVID-19 patients, use of Thymalin decreased blood levels of fibrinogen, lactate dehydrogenase and D-dimer by 1,2, 1,8 and 1,7 times, respectively. In severe COVID-19 patients, Thymalin increased the number of lymphocytes and monocytes by 2 times.
In a human clinical trial of middle-aged and elderly patients with severe COVID-19, Thymalin, compared with Tocilizumab, was concluded to meet the principles of pathogenic therapy to a greater extent. In that trial, Thymalin was reported to have a normalizing effect on the morphological composition and indicators of the blood clotting system.
In experiments on albino outbred male rats with transplanted sarcoma 45, Thymalin showed a pronounced antitumor effect at doses lower than the therapeutic doses. In these rats, tumor growth arrest and regression were observed in more than half of the animals, and in other cases tumor growth was suppressed by 78%. In the rats, tumor regression was accompanied by the development of stable antistress adaptation reactions of calm and elevated activation.
In animal studies, Thymalin reduced the threshold of sensitivity of arcuate nucleus neurons of the hypothalamus to the action of stress. The source describes this as Thymalin reducing the sensitivity threshold of the neuron's arcuate center to stress, so these neurons reacted to stress at a lower level. A separate animal finding involved stress exposure and alpha-tocopherol injection in young animals, which reduced the kernels of arcuate nucleus neurons, with no sex difference revealed in this process; this was not a Thymalin result.
In old mice, FTS level increased after administration of thymalin, and the rhythm of CD4+ cell number in bone marrow and serum corticosterone content were restored. In old mice, FTS content also increased after thymalin injection, while corticosterone level did not change.
In a study in rats with lower jaw bone defects, the authors concluded that stimulating local immune reactions by thymalin injection may be one mechanism activating reparative osteogenesis, that is, bone repair. This applied when bone defects were filled with the hydroxyapatite-containing material Biomin GT and thymalin was injected into the surrounding soft tissues.
The findings state that Thymalin accumulates only in young cells of the skin ectodermal epithelium and in the mucosa of the anterior portions of the digestive and respiratory systems. Thymalin content in the ectodermal epithelium of organs undergoes age-associated involution, similar to what happens in the thymus. After keratin appears in cells, they no longer accumulate Thymalin.
In a human clinical trial in children with secretory otitis media, those who received thymalin-based regimens had the fewest relapses of the condition. These same children also showed the best immunity indicators.
FOR RESEARCH USE ONLY — Products are sold exclusively for in vitro and preclinical laboratory research. Not for human consumption or administration. Not intended for diagnostic or therapeutic use. These statements have not been evaluated by the FDA.